Rosiglitazone
- Generic Name
- Rosiglitazone
- Brand Names
- Avandamet, Avandia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O3S
- CAS Number
- 122320-73-4
- Unique Ingredient Identifier
- 05V02F2KDG
- Background
Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellula...
- Indication
Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue
- Conditions
- Interventions
- First Posted Date
- 2010-06-25
- Last Posted Date
- 2012-03-26
- Lead Sponsor
- University of Massachusetts, Worcester
- Target Recruit Count
- 35
- Registration Number
- NCT01150981
- Locations
- 🇺🇸
UMass Medical School, Worcester, Massachusetts, United States
A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 40
- Registration Number
- NCT01100619
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Jean-Patrice Baillargeon
- Target Recruit Count
- 52
- Registration Number
- NCT01019356
- Locations
- 🇨🇦
Université de Sherbrooke, Sherbrooke, Quebec, Canada
Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 7641
- Registration Number
- NCT00995995
Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 87
- Registration Number
- NCT00964106
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2013-09-02
- Lead Sponsor
- Centre Hospitalier Universitaire Dijon
- Target Recruit Count
- 40
- Registration Number
- NCT00953498
- Locations
- 🇫🇷
Service Endocrinologie-diabétologie, Hôpital du Bocage CHU, Dijon, France
The Impact of Obesity and Obesity Treatments on Breast Cancer
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00933309
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Thiazolidinedione Intervention With Vitamin D Evaluation
- Conditions
- Interventions
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1332
- Registration Number
- NCT00879970
- Locations
- 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom
A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs
- Conditions
- Interventions
- First Posted Date
- 2009-01-28
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 53
- Registration Number
- NCT00831129
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)
- First Posted Date
- 2009-01-09
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- Ahmad Slim
- Target Recruit Count
- 41
- Registration Number
- NCT00819910
- Locations
- 🇺🇸
Brooke Army Medical Center, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.